1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality

Technology appraisal guidance [TA322] Published date: 24 September 2014 Last updated: 26 June 2019

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History
  • Overview
  • 1 Guidance
  • 2 The technology
  • 3 The company's submission
  • 4 Consideration of the evidence
  • 5 Implementation
  • 6 Recommendations for further research
  • 7 Appraisal Committee members, guideline representatives and NICE project team
  • 8 Sources of evidence considered by the Committee
  • Update information
  • Share
    • Share
    • Linked In
    • Twitter
    • Facebook
    • Email
    • More...
  • Download
    • Save
    • Save as PDF
    • Save as ePub
    • Save as eBook

Guidance

Update information

Update information

June 2019: Sections 1 and 2 updated to include a new commercial arrangement. Standard text in implementation section updated.

ISBN: 978‑4731‑0751‑9

  • National Institute for Health and Care Excellence (NICE)